Extracavitary/solid variant of primary effusion lymphoma

Kim, Yoonjung; Leventaki, Vasiliki; Bhaijee, Feriyl; Jackson, Courtney; Medeiros, L. Jeffrey; Vega, Francisco

doi:10.1016/j.anndiagpath.2012.03.004

Cited by 66 publications

(42 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It typically arises in a body cavity as a lymphomatous effusion without an associated solid tumor mass. However, since its initial description, an extracavitary (or solid) variant has been described that may or may not be associated with a malignant serous effusion (8,9). In cases associated with serous effusion, these extracavitary PELs can occur prior to or following the effusion (10,11,12).…”

Section: Discussionmentioning

confidence: 98%

Case Study Interpretation - Fort Lauderdale: Case 4

Fuda

2013

Cytometry

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Case Study Interpretation - Fort Lauderdale: Case 4

Fuda

2013

Cytometry

View full text Add to dashboard Cite

“…It was officially recognized as a distinct entity in the 2001 World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues (4). However, since its initial description, an extracavitary (or solid) variant has been described that may or may not be associated with a malignant serous effusion (8,9). HIV(1) patients that develop PEL usually have an absolute CD4 count below 100 cells/lL.…”

Section: Discussionmentioning

confidence: 99%

Case study interpretation-Fort Lauderdale: Case 4

Fuda

2014

Cytometry

View full text Add to dashboard Cite

How to cite this article: Fuda FS. Case study interpretation -Fort Lauderdale: Case 4. Cytometry Part B 2015; 86B: 408-412. CASE HISTORYA 46-year-old Hispanic man presented to his primary care physician with "chest pressure" and shortness of breath upon exertion. He had a past medical history of acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma, for which he was status post chemotherapy with complete response two years prior to the current visit. He was compliant for highly active antiretroviral therapy (HAART). His current CD4 T-cell absolute count was 176 cells/lL (Nl range 416-1751). A chest X-ray and an echocardiogram revealed significant pericardial effusion with cardiac tamponade. He underwent a pericardiocentesis with placement of a drain. The pericardial fluid was bloody with a high lactate dehydrogenase (LDH) and contained 5,240 nucleated cells/lL. Seventy-nine percent of the fluid cells were interpreted as "atypical cells." The fluid was sent to flow cytometry and cytology for further work up. A complete blood count (CBC) with differential count showed a mild lymphopenia.

show abstract

“…Morphologically, plasmablastic myeloma can be indistinguishable from PEL. Neoplastic plasma cells express CD138 and cytoplasmic IgG, may express CD79a, CD56, and cyclin D1, and may not express CD45 or CD30 39,40,41…”

Section: Differential Diagnosismentioning

confidence: 99%

“…In large B-cell lymphoma associated with multicentric Castleman's disease, cells harbor non-mutated Ig variable region genes and are derived from CD27- and CD138-negative naive B-cells. By contrast, PEL cells usually express CD138 and harbor hypermutated rearranged Ig genes, suggesting they originate from germinal center or post-germinal center B cells 41,43. Whereas PEL is commonly associated with EBV infection, large B-cell lymphoma associated with multicentric Castleman's disease is not 41,43…”

Section: Differential Diagnosismentioning

confidence: 99%

Current Concepts in Primary Effusion Lymphoma and Other Effusion-Based Lymphomas

et al. 2014

Self Cite

View full text Add to dashboard Cite

Primary effusion lymphoma (PEL) is a human herpes virus 8 (HHV8)-positive large B-cell neoplasm that presents as an effusion with no detectable tumor in individuals with human immunodeficiency virus infection or other immune deficiencies. PEL is an aggressive neoplasm with a poor prognosis. PEL cells show diverse morphologies, ranging from immunoblastic or plasmablastic to anaplastic. The immunophenotype of PEL is distinct, but its lineage can be misdiagnosed if not assessed thoroughly. PEL cells usually express CD45, lack B- and T-cell-associated antigens, and characteristically express lymphocyte activation antigens and plasma cell-associated antigens. Diagnosis of PEL often requires the demonstration of a B-cell genotype. HHV8 must be detected in cells to diagnose PEL. In most cases, PEL cells also harbor the Epstein-Barr virus (EBV) genome. Similar conditions associated with HHV8 but not effusion-based are called "extracavitary PELs." PELs should be differentiated from HHV8-negative, EBV-positive, body cavity-based lymphomas in patients with long-standing chronic inflammation; the latter can occur in tuberculous pleuritis, artificial pneumothorax, chronic liver disease and various other conditions. Despite their morphological similarity, these various lymphomas require different therapeutic strategies and have different prognostic implications. Correct diagnosis is essential to manage and predict the outcome of patients with PEL and related disorders.

show abstract

Extracavitary/solid variant of primary effusion lymphoma

Cited by 66 publications

References 29 publications

Case Study Interpretation - Fort Lauderdale: Case 4

Case Study Interpretation - Fort Lauderdale: Case 4

Case study interpretation-Fort Lauderdale: Case 4

Current Concepts in Primary Effusion Lymphoma and Other Effusion-Based Lymphomas

Contact Info

Product

Resources

About